Bank of America’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Bank of America’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-800	Closed	-$4K	–	8109
2014 Q3	$4K	Buy	+800	New	+$3.99K	﹤0.01%	7636

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Bank of America's PGNX Position: Q2 2020 in Review

Bank of America sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 65,327 shares — an estimated $248K sold.

Bank of America first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $4.29M in Q3 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Bank of America reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Bank of America sold 65,327 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $248K.
Bank of America first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
Bank of America's Progenics Pharmaceuticals Inc position peaked at $4.29M in Q3 2017.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Bank of America's 13F filing for Q2 2020, filed 14 Aug 2020.